Overview of Echnatol B6

What is Echnatol B6?

Echnatol B6 is a combined therapeutic agent formulated to address specific symptoms related to metabolic imbalances and vestibular disturbances. It consists of two primary active components: Meclizine hydrochloride and Pyridoxine hydrochloride (Vitamin B6). These ingredients work in coordination to provide relief from nausea and dizziness.

Composition and Mechanism

Meclizine Hydrochloride: This component belongs to the class of first-generation antihistamines. It primarily acts as an H1 receptor antagonist and possesses anticholinergic properties. In the context of Echnatol B6, it is utilized for its ability to reduce the sensitivity of the labyrinthine apparatus in the inner ear and inhibit the triggers in the chemoreceptor trigger zone that lead to nausea.
Pyridoxine Hydrochloride (Vitamin B6): This is a water-soluble vitamin essential for numerous physiological functions, including amino acid metabolism and the synthesis of neurotransmitters. In this formulation, Pyridoxine is included to support metabolic processes and has been observed to assist in the management of certain types of nausea, particularly when associated with metabolic or hormonal changes.

Therapeutic Purpose

The primary function of Echnatol B6 is to stabilize the vestibular system and mitigate the sensation of vertigo and associated vomiting. By combining an antihistamine with a metabolic cofactor, the preparation aims to manage the underlying physiological signals that cause equilibrium disruptions. It is commonly utilized in clinical settings to manage symptoms arising from motion sickness or inner ear disorders.

What side effects are possible with Echnatol B6?

Official Safety Characteristics

The safety profile of Echnatol B6 is defined by the official classification of its possible adverse reactions, which are grouped according to frequency and the body's system-organ classes (SOC) in regulatory documents.

Reactions categorized as common in official labeling primarily affect the nervous system and include drowsiness and sedation, along with the anticholinergic effect of dry mouth. Reactions classified as uncommon across various SOC groups include headache, blurred vision, constipation, tachycardia (increased heart rate), and urinary retention.

Classification	Examples of Documented Adverse Reactions
Common	Drowsiness, Sedation, Dry mouth
Uncommon	Headache, Blurred vision, Constipation
Rare	Hepatitis, Jaundice, Hypotension, Hallucinations

Serious Adverse Reactions and Population Constraints

Certain adverse reactions are officially classified as rare and include more serious systemic effects, such as hepatitis and jaundice, along with hypotension (low blood pressure) and severe hypersensitivity reactions, including angioedema. These are explicitly documented in regulatory sources.

Safety considerations for special populations are also defined. Official labels note an increased potential for reactions such as sedation and confusion in older adults. Furthermore, the anticholinergic properties of the medicine can impose safety limitations for individuals with pre-existing conditions like angle-closure glaucoma or prostatic hypertrophy.

Safety limitations regarding concurrent use are highlighted, specifically the potential for enhanced central nervous system (CNS) depression when Echnatol B6 is used with alcohol or other pharmaceutical agents known to depress the CNS.

Overdose and Emergency Response

The official regulatory profile for an Echnatol B6 overdose is defined by the severe effects of its active component, Cyclizine, which primarily targets the Central Nervous System (CNS) and manifests as anticholinergic toxicity.

Documented Overdose Manifestations

Overdose may present with pronounced CNS disturbances, including drowsiness, somnolence, disorientation, or, conversely, hyperexcitability and hallucinations (visual and auditory). Signs of anticholinergic toxicity include tachycardia (rapid heart rate), blurred vision, dry mouth, and urinary retention.

Severe Outcomes and Emergency Actions

Regulatory documents highlight the potential for life-threatening outcomes, such as convulsions (seizures), respiratory depression, and hyperpyrexia. A specific pharmacological antidote is not consistently listed across official documentation; therefore, management focuses on supportive care.

When Immediate Medical Help is Required

When an overdose is known or suspected, immediate assessment and treatment are essential. Regulatory authorities explicitly mandate that individuals seek emergency medical attention or contact a Poison Control Center without delay. Younger children are documented as being more susceptible to severe CNS effects, particularly convulsions, following overdose. Management procedures include supportive measures for circulation and respiration and, if necessary, the use of parenteral anticonvulsant therapy.

Therapeutic Uses of Echnatol B6

What Echnatol B6 Treats: Main Uses and Benefits

The fixed-dose combination of Cyclizine and Pyridoxine is commonly used across therapeutic domains involving certain distressing symptoms, primarily related to motion and balance. It is relevant when supportive symptom management is appropriate for symptoms that create noticeable physiological strain.

The medication is applied in addressing symptom clusters that may become intense or disruptive, specifically nausea, vomiting, and vertigo (dizziness). It is commonly used across conditions presenting with acute episodes, including managing motion sickness, supporting patients through sickness following general anesthesia or radiotherapy, and easing symptoms related to inner ear conditions like Ménière's disease.

This therapeutic approach contributes to improved comfort during periods of heightened symptoms. The dual action may support a feeling of greater stability and helps maintain a sense of stability when symptoms are more noticeable.

“The primary benefit of this medication is its ability to offer symptomatic relief, which helps maintain a sense of stability when distressing symptoms are more noticeable.”

Quick Fact: Relief for Systemic Discomfort

Symptom Domain	Common Contexts of Use	Supportive Therapeutic Role
Sickness and Vomiting	Post-anesthesia, certain medical treatments, acute illness.	Contributes to easing the overall symptom load.
Dizziness and Vertigo	Vestibular disturbances, Ménière's disease, acute spinning.	Assists with maintaining functional stability.
Motion Sickness	Planned travel, journeys, or unpredictable movement.	Supports day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Echnatol B6?

This section details the population eligibility and restrictions for Echnatol B6, a fixed-dose combination of Cyclizine and Pyridoxine, based strictly on official governmental regulatory documents.

Eligibility Status by Population Group

Status	Population Group	Regulatory Condition
Allowed	Adults and Adolescents (12+ years)	Approved for standard use.
Allowed	Children (6 to 11 years)	Approved for use.
Not Recommended	Children less than 6 years	Officially not recommended due to lack of established data.
Contraindicated	Hypersensitivity (to ingredients/excipients)	Absolute prohibition.
Contraindicated	Porphyria, Acute Alcohol Intoxication	Absolute prohibition.

Restrictions and Conditional Use

Certain patient populations require caution or are subject to restrictions as stated in the official label:

Comorbidities: Use requires caution in patients with conditions such as Glaucoma, Epilepsy, Hypertension, severe heart failure, or pre-existing obstructive gastrointestinal disease.
Organ Function: Caution and close monitoring are necessary for individuals with hepatic (liver) impairment.
Pregnancy and Lactation: Use during these periods is governed by a health professional, as the primary component is classified as FDA Category B, but data on excretion into breast milk is often not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Echnatol B6 (Cyclizine/Pyridoxine) primarily through pharmacodynamic interactions that result in additive effects. Co-administration with certain substances is contraindicated or requires specific caution due to documented outcomes.

Contraindicated Combinations

The co-administration of Echnatol B6 with Acute Alcohol Intoxication is formally contraindicated. This restriction exists because the anti-emetic action of Cyclizine is officially stated to increase the toxicity of alcohol and mask symptoms of intoxication. Avoidance of alcohol is mandatory when taking this medication.

Documented Pharmacodynamic Interactions

The official labeling notes several interactions based on additive effects:

Central Nervous System (CNS) Depressants: Co-administration with other CNS depressants, including tranquillisers, hypnotics, anaesthetics, antipsychotics, and barbiturates, has additive depressant effects. These combinations may lead to increased drowsiness.
Anticholinergic Drugs: There is an additive antimuscarinic action when Echnatol B6 is taken with other anticholinergic agents (such as certain antidepressants and MAOIs), potentially enhancing their effects.
Ototoxic Drugs: The drug may mask the warning signs of damage to the inner ear when co-administered with ototoxic drugs, such as aminoglycoside antibacterials.

Patients with underlying hepatic or renal disease may have an increased risk for accumulation of the drug and its metabolites, which can heighten the potential for these documented pharmacodynamic interactions.

Mechanism of Action

The combined pharmacodynamic action of Cyclizine and Pyridoxine (Vitamin B6) influences central nervous system pathways to modulate central signals in the emetic reflex arc. The mechanism is defined by dual molecular engagement and complementary action.

Modulation of Central Vestibular Signal Transmission

Cyclizine, the primary active component, acts as a competitive antagonist at central Histamine H1 receptors and blocks muscarinic cholinergic receptors in the brainstem. This signal blockade functionally depresses the excitability of the vestibular nuclei, the neuronal center that processes afferent signals from the labyrinth. This activity increases the required magnitude of stimulation to activate the medullary vomiting center.

Metabolic Modulation of Central Neurotransmitter Availability

The Pyridoxine component provides a distinct mechanism by acting as a precursor to the coenzyme Pyridoxal 5-Phosphate (PLP). PLP is a required co-factor for enzymes critical in synthesizing inhibitory neurotransmitters, such as GABA. This metabolic facilitation supports the necessary pathways for synthesizing inhibitory neurotransmitters, complementing the primary receptor-mediated suppression achieved by Cyclizine.

Dosage and Administration Information

How to Use Echnatol B6: Official Administration Guidelines

Echnatol B6 is an oral tablet that delivers a fixed combination of Cyclizine and Pyridoxine Hydrochloride. Usage is structured by specific rules regarding dosage, frequency, and timing to ensure consistent administration.

Administration Scope

Feature	Guideline
Route of administration:	Oral administration only for the tablet dosage form, to be swallowed with water.
Dosing schedule (Adults):	Standard unit dose is 50 mg (Cyclizine component). Maximum adult daily dose is 150 mg.
Timing in relation to meals:	May be taken with or without food.
Age-group administration rules:	Children 6–12 years: The recommended dose is 25 mg (half-tablet) up to three times a day. Children under 6 years: Use is not recommended for the tablet form.

Instruction Classifications (High-Level)

Classification	Parameter
Administration method type:	Oral tablet.
Frequency pattern:	As-needed or prophylactic use, up to a limit of three times a day (TID).
Use-context constraints:	For prophylactic use, the initial dose should be taken approximately one to two hours before departure.

Resulting Procedural Structure

The official instruction sequence establishes a clear use pattern:

Dose Unit: Administering the 50 mg unit dose (adults) or 25 mg divided dose (children 6–12 years) by swallowing the tablet with water.
Repetition: Repeating the dose up to a maximum of three times per day, with a recommended interval of approximately 8 hours between administrations.
Prophylaxis Timing: When used preventatively, the initial unit dose must be taken 1 to 2 hours before travel.

This framework ensures the medicine is used within the limits of 150 mg daily and dictates the appropriate temporal spacing of doses.

Recent Clinical Evidence

Research evidence / Overview of Studies for Echnatol B6

This section provides an overview of the types of official research that have studied the use of Echnatol B6, a combination of Cyclizine and Pyridoxine, for its intended purposes. The text summarizes the existing evidence base, highlighting what has been observed in studies and what aspects remain uncertain.

Evidence for Use in Acute Nausea, Vomiting, and Vertigo

Research has studied this combination in contexts related to conditions characterized by fluctuating or episodic manifestations of sickness and dizziness. Trials have evaluated the medicine for use in acute vertigo and symptoms of motion sickness. These studies included populations of adults and older adults experiencing systemic or functional imbalance related to the inner ear.

In these trials, researchers primarily examined outcomes related to functional assessments of stability and patient reports of perceived discomfort. Findings describing patterns observed in these studies are drawn from historical evidence and research on the single Cyclizine component, which has been associated with the vestibular system. However, the evidence is limited when looking for modern, large-scale placebo-controlled RCTs specifically testing the fixed combination in these settings.

Research on Postoperative Nausea and Vomiting (PONV)

The anti-emetic component of Echnatol B6 was studied for use in acute or disruptive episodes of sickness following general anesthesia. Research utilized Randomized Controlled Trials (RCTs) to monitor outcomes related to physical discomfort in adult surgical patients identified as being at risk for sickness after an operation.

These studies monitored the incidence rates of nausea and vomiting and the rate at which rescue medications were required. The evidence base for the use of the combination in this context is frequently explored in studies evaluating the principal Cyclizine component in comparison with other established agents. Comparative evidence is lacking specifically for the fixed combination against placebo in this surgical population, and the follow-up durations were limited.

What Is Still Uncertain About the Research for Echnatol B6

A primary limitation is that much of the research relies on the existing findings for the Cyclizine monocomponent, leading to uncertainty regarding the incremental contribution of the Pyridoxine component in the fixed-dose formulation. Furthermore, evidence quality varies across studies, and for some indications, the data available for the combination are historical and have been identified as having a high risk of bias. Comparative evidence is lacking in several areas, making it difficult to contextualize its use alongside contemporary standard therapies.

Key Studies & References

Management of nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum (HG) (RCOG Guideline)

Frequently Asked Questions (FAQ)

Common questions about Echnatol B6 (FAQ)

Q: What is the significance of 'B6' in the drug name Echnatol B6?

According to official product information, Echnatol B6 contains Pyridoxine Hydrochloride, commonly known as Vitamin B6. This essential nutrient acts as a necessary co-factor in the body, and its role is recognized in the management of symptoms of nausea and vomiting. The presence of Vitamin B6 complements the primary anti-sickness mechanism of the Cyclizine component.

Q: What are the official regulatory classifications of Echnatol B6 in major countries?

Official regulatory bodies classify Echnatol B6 as a combination medication: specifically, an antihistamine (H1-receptor antagonist) paired with a vitamin. The specific legal status of the medicine—such as whether it requires a prescription or is available over-the-counter—is determined by individual national health authorities, rather than the pharmacological classification alone.

Q: What does official guidance say about the use of Echnatol B6 during pregnancy or breastfeeding?

Official guidance notes that use during pregnancy requires assessment by a health professional. Furthermore, information regarding the medicine's excretion into breast milk is often not established in official documents. Therefore, consultation with a professional is important to discuss the potential risks and benefits during breastfeeding.

Q: Is it safe to use Echnatol B6 concurrently with common cold or flu medications?

Regulatory documents indicate that caution is advised when Echnatol B6 is used with other Central Nervous System (CNS) depressants, as this can cause additive effects like increased drowsiness. Many common cold and flu medications may contain ingredients that act as CNS depressants. Reviewing the product label for any concurrent medication is recommended to identify these ingredients.

Q: Can Echnatol B6 be crushed or split if a person has trouble swallowing?

For the standard oral tablet formulation, the tablet may be physically altered (crushed or split) when authorized, such as when a half-tablet dose is prescribed. However, the tablet should not be split, chewed, or crushed if it is specifically designated as a delayed-release or extended-release formulation.

Q: How long does Echnatol B6 typically take before an effect might be noticeable?

Studies on the anti-emetic component (Cyclizine) indicate that the onset of action typically begins within approximately 30 minutes after the tablet is taken orally. This is the time required for the active substance to begin influencing the body's sickness pathways.

Q: Are the reported side effects of Echnatol B6 generally temporary?

Official product information indicates that common adverse reactions, such as drowsiness and dry mouth, are usually mild in nature. These effects may often resolve on their own as the body adapts to the medicine.

Q: What is the known evidence regarding the use of Echnatol B6 for extended periods (long-term)?

The research evidence for continuous, long-term use is limited. Regulatory information generally references use for acute episodes rather than continuous use.

Q: Is Echnatol B6 known to cause changes in weight (gain or loss)?

Adverse reaction reporting documented in official sources has included instances of decreased appetite or loss of appetite. This is considered a potential, but not guaranteed, effect of the medicine.

Q: Is there any risk of dependency or withdrawal associated with Echnatol B6?

Regulatory documents contain reports of dependence and abuse associated with the active component, particularly when administered intravenously. Due to this documented risk, monitoring by a healthcare professional is noted as important.

Q: What should a patient generally know if they accidentally miss a dose of Echnatol B6?

Official instructions typically state that if the medicine is used on an 'as-needed' basis, the timing of a missed dose is not relevant. If it is part of a scheduled treatment, a dose may be taken when remembered, or skipped if close to the next scheduled time. Do not take a double dose.

Q: How quickly does Echnatol B6 clear from the body after discontinuation?

Pharmacokinetic studies show that the anti-emetic component (Cyclizine) has a half-life of approximately 14 to 20 hours. The half-life is the time it takes for half of the active substance to be eliminated from the body, and this timeframe dictates the overall clearance of the medicine.

Q: What is the usual recommended duration of treatment with Echnatol B6?

The official recommended duration of treatment is specific to the condition being treated. Treatment is generally intended for acute or episodic use, and usage duration is determined by the healthcare provider based on the specific condition.

How should Echnatol B6 be stored and disposed of?

How to Store and Dispose of Echnatol B6

The official labeling mandates specific storage and disposal rules for Echnatol B6 (Cyclizine and Pyridoxine Hydrochloride) to maintain product quality and integrity.

Storage Conditions

Detail	Regulatory Requirement
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection	Must be protected from light, excess heat, and moisture. Do not freeze.
Container	Keep out of the sight and reach of children and store in the original, tightly closed container.

Disposal Instructions

Unused or expired Echnatol B6 must be handled as pharmaceutical waste. Do not dispose of the medication in household trash or pour it down a sink or toilet (wastewater). The product must be disposed of according to local regulations or returned to a designated collection site.

Echnatol B6